Chugai partners with Gero for antibody drugs using AI technology, gaining exclusive global rights.

Chugai Pharmaceutical partners with Gero to develop antibody drugs for age-related conditions using AI technology. Chugai gains exclusive global rights to research, develop, and commercialize these treatments. The collaboration involves an initial payment to Gero and potential additional payments up to $250m based on milestones. Chugai’s CEO emphasizes the importance of open innovation for drug discovery. Gero was represented by Ropes & Gray in the agreement. In a separate collaboration, Chugai and Araris Biotech formed a $780m research agreement for antibody-drug conjugates in January 2025.

Read more at Yahoo Finance: Chugai and Gero link on antibody drugs for age-related conditions